Trial Profile
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Cerebrovascular disorders; Intracranial-Arteriosclerosis; Stroke
- Focus Proof of concept; Therapeutic Use
- Acronyms PINNACLE
- 18 Apr 2020 Status changed from recruiting to discontinued.
- 23 Jan 2020 Planned End Date changed from 28 Sep 2021 to 28 Sep 2022.
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.